Publikationen in Zusammenarbeit mit Forschern von University of the Witwatersrand (1)

2017

  1. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

    The Lancet HIV, Vol. 4, Núm. 11, pp. e486-e494